Ciba-Geigy/Synergen
Executive Summary
An agreement covering the development of recombinant elastase inhibitor for the treatment of emphysema was expanded to cover scale-up and commercial manufacturing. The arrangement calls for Synergen to deliver quantities of elastase inhibitor to Ciba-Geigy by the second half of 1987. The Boulder, Colo.-based biotech firm is currently constructing a $4 mil. pilot production facility that is scheduled for completion this summer.